173 related articles for article (PubMed ID: 17579460)
1. Zinc binding in HDAC inhibitors: a DFT study.
Wang D; Helquist P; Wiest O
J Org Chem; 2007 Jul; 72(14):5446-9. PubMed ID: 17579460
[TBL] [Abstract][Full Text] [Related]
2. DFT-based ranking of zinc-binding groups in histone deacetylase inhibitors.
Vanommeslaeghe K; Loverix S; Geerlings P; Tourwé D
Bioorg Med Chem; 2005 Nov; 13(21):6070-82. PubMed ID: 16006131
[TBL] [Abstract][Full Text] [Related]
3. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Finnin MS; Donigian JR; Cohen A; Richon VM; Rifkind RA; Marks PA; Breslow R; Pavletich NP
Nature; 1999 Sep; 401(6749):188-93. PubMed ID: 10490031
[TBL] [Abstract][Full Text] [Related]
4. Comparative molecular dynamics simulations of histone deacetylase-like protein: binding modes and free energy analysis to hydroxamic acid inhibitors.
Yan C; Xiu Z; Li X; Li S; Hao C; Teng H
Proteins; 2008 Oct; 73(1):134-49. PubMed ID: 18398905
[TBL] [Abstract][Full Text] [Related]
5. On the function of the 14 A long internal cavity of histone deacetylase-like protein: implications for the design of histone deacetylase inhibitors.
Wang DF; Wiest O; Helquist P; Lan-Hargest HY; Wiech NL
J Med Chem; 2004 Jun; 47(13):3409-17. PubMed ID: 15189037
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation, and molecular docking of Ugi products containing a zinc-chelating moiety as novel inhibitors of histone deacetylases.
Grolla AA; Podestà V; Chini MG; Di Micco S; Vallario A; Genazzani AA; Canonico PL; Bifulco G; Tron GC; Sorba G; Pirali T
J Med Chem; 2009 May; 52(9):2776-85. PubMed ID: 19344175
[TBL] [Abstract][Full Text] [Related]
7. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design.
Suzuki T; Matsuura A; Kouketsu A; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2005 Jan; 15(2):331-5. PubMed ID: 15603949
[TBL] [Abstract][Full Text] [Related]
8. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
9. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases.
Wang DF; Helquist P; Wiech NL; Wiest O
J Med Chem; 2005 Nov; 48(22):6936-47. PubMed ID: 16250652
[TBL] [Abstract][Full Text] [Related]
10. A series of novel, potent, and selective histone deacetylase inhibitors.
Jones P; Altamura S; Chakravarty PK; Cecchetti O; De Francesco R; Gallinari P; Ingenito R; Meinke PT; Petrocchi A; Rowley M; Scarpelli R; Serafini S; Steinkühler C
Bioorg Med Chem Lett; 2006 Dec; 16(23):5948-52. PubMed ID: 16987657
[TBL] [Abstract][Full Text] [Related]
11. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors.
Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C
Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors.
Krennhrubec K; Marshall BL; Hedglin M; Verdin E; Ulrich SM
Bioorg Med Chem Lett; 2007 May; 17(10):2874-8. PubMed ID: 17346959
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment.
Chen Y; Li H; Tang W; Zhu C; Jiang Y; Zou J; Yu Q; You Q
Eur J Med Chem; 2009 Jul; 44(7):2868-76. PubMed ID: 19136179
[TBL] [Abstract][Full Text] [Related]
15. A structure-based virtual screening approach toward the discovery of histone deacetylase inhibitors: identification of promising zinc-chelating groups.
Park H; Kim S; Kim YE; Lim SJ
ChemMedChem; 2010 Apr; 5(4):591-7. PubMed ID: 20157916
[TBL] [Abstract][Full Text] [Related]
16. Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.
Giannini G; Marzi M; Marzo MD; Battistuzzi G; Pezzi R; Brunetti T; Cabri W; Vesci L; Pisano C
Bioorg Med Chem Lett; 2009 May; 19(10):2840-3. PubMed ID: 19359173
[TBL] [Abstract][Full Text] [Related]
17. Exploring alternative Zn-binding groups in the design of HDAC inhibitors: squaric acid, N-hydroxyurea, and oxazoline analogues of SAHA.
Hanessian S; Vinci V; Auzzas L; Marzi M; Giannini G
Bioorg Med Chem Lett; 2006 Sep; 16(18):4784-7. PubMed ID: 16870438
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective HDAC inhibition from cysteine-derived zinc-binding groups.
Butler KV; He R; McLaughlin K; Vistoli G; Langley B; Kozikowski AP
ChemMedChem; 2009 Aug; 4(8):1292-301. PubMed ID: 19551801
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
20. Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.
Bhuiyan MP; Kato T; Okauchi T; Nishino N; Maeda S; Nishino TG; Yoshida M
Bioorg Med Chem; 2006 May; 14(10):3438-46. PubMed ID: 16439135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
